Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency

Fondazione Salvatore Maugeri100 enrolled

Overview

In the context of the increasing evidence of the pathogenetic role of microbiome in COPD, our aim is to determine the total and specific bacterial and viral load in sputa from patients with COPD due to AATD and to correlate these findings with cellular, biochemical and immunological characteristics of sputa. These quantitative data obtained from sputum will be analyzed in the context of the clinical and physiological parameters of the patients.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Alpha-1 Antitrypsin Deficiency

Interventions

collection of sputumOTHER

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of COPD and a clinical stable condition, i.e. at least three months from the last AECOPD and/or antibiotic treatment. For patients with AATD this condition will be diagnosed by laboratory tests showing low levels of AAT and genotyping of AATD-related genes. . Exclusion Criteria: * The presence of important co-morbidities (diabetes, systemic or organ infections, immunodeficiency, tumors, moderate-severe heart failure) will be considered as exclusion criteria.

Outcomes

Primary Outcomes

composition of microbioma in sputa

Time frame: 2 years

Secondary Outcomes

correlation with clinical and physiological parameters

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.